Skip to main navigation

>> Site Menu

Our Company
Our Pipeline
Our Science
Join Us
INVESTORS & MEDIA

Kodiak Sciences

>> Site Menu

Our Company
Our Pipeline
Our Science
Join Us
INVESTORS & MEDIA

News Releases

> News - Sub Nav

Press Releases

News Releases

September 15, 2019

Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting

Additional Formats

PDF Version

September 12, 2019

Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting

Additional Formats

PDF Version

September 6, 2019

Kodiak Sciences to Present at the Morgan Stanley Global Healthcare Conference

Additional Formats

PDF Version

September 4, 2019

Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting

Additional Formats

PDF Version

August 14, 2019

Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

August 8, 2019

Kodiak Sciences to Present at Wedbush PacGrow Healthcare Conference

Additional Formats

PDF Version

July 27, 2019

Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina Specialists 2019 Annual Meeting

Additional Formats

PDF Version

July 24, 2019

Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting

Additional Formats

PDF Version

May 30, 2019

Kodiak Sciences to Present at the Jefferies 2019 Healthcare Conference

Additional Formats

PDF Version

May 15, 2019

Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 28

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

Kodiak Sciences

2631 Hanover Street
Palo Alto, CA 94304
info@kodiak.com

Copyright © 2019 Kodiak Sciences Inc..